Top

Published in:

01-05-2011

Continuous dopaminergic stimulation and novel formulations of dopamine agonists

Author: Fabrizio Stocchi

Published in: Journal of Neurology | Special Issue 2/2011

Abstract

There is now accumulating evidence that the combination of progressive pathology of Parkinson’s disease, the change in drug pharmacodynamics, and the pulsatile manner in which short-acting dopaminergic agents stimulate striatal dopamine receptors are the key contributing factors to the priming of the basal ganglia for induction of motor complications. Long-acting drugs provide a more physiological dopaminergic stimulation. Dopamine agonists have been extensively used as monotherapy and add-on therapy to levodopa to treat Parkinson’s disease in the early stage and with motor complications. Today, the new long-acting formulation offers the advantages of an easy use and a more continuous delivery of drug. In this paper the role of new formulations of dopamine agonists in the treatment of parkinsonian patients at different stages of the disease is reviewed.

Olanow CW, Watts RL, Koller WC (2001) An algorithm (decision tree) for the management of Parkinson’s disease: treatment guidelines. Neurology 56(Suppl 5):S1–S86PubMed

Agid Y, Olanow C, Mizuno Y (2002) Levodopa: why the controversy? Lancet 360:575PubMedCrossRef

Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE (2002) Practice parameter: initiation of treatment for Parkinson’s disease: an evidence-based review. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 58:11–17

Rascol O, Goetz C, Koller W, Poewe W, Sampaio C (2002) Treatment interventions for Parkinson’s disease: an evidence-based assessment. Lancet 359:1589–1598PubMedCrossRef

Korczyn AD, Nussbaum M (2002) Emerging therapies in the pharmacological treatment of Parkinson’s disease. Drugs 62:775–786PubMedCrossRef

Marsden CD, Parkes JD (1977) Success and problems of long-term levodopa therapy in Parkinson’s disease. Lancet 1:345–349PubMedCrossRef

Marsden CD (1994) Parkinson’s disease. J Neurol Neurosurg Psychiatry 57:672–681PubMedCrossRef

Luquin MR, Scipioni O, Vaamonde J, Gershanik O, Obeso JA (1992) Levodopa-induced dyskinesias in Parkinson’s disease: clinical and pharmacological classification. Mov Disord 7:117–124PubMedCrossRef

Marconi R, Lefebvre-Caparros D, Bonnet AM, Vidailhet M, Dubois B, Agid Y (1994) Levodopa-induced dyskinesias in Parkinson’s disease: phenomenology and pathophysiology. Mov Disord 9:2–12PubMedCrossRef

10.

Stocchi F (2009) The hypothesis of the genesis of motor complications and continuous dopaminergic stimulation in the treatment of Parkinson’s disease. Parkinsonism Relat Disord 15(Suppl 1):S9–S15 (Review)

11.

Stacy M, Bowron A, Guttman M, Hauser R, Hughes K, Larsen JP et al (2005) Identification of motor and non motor wearing-off in Parkinson’s disease: Comparison of a patient questionnaire versus a clinician assessment. Mov Disord 20:726–733PubMedCrossRef

12.

Olanow CW, Obeso JA, Stocchi F (2006) Continuous dopamine-receptor treatment of Parkinson’s disease: scientific rationale and clinical implications. Lancet Neurol 5:677–687PubMedCrossRef

13.

Grace AA (1991) Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 41:1–24PubMedCrossRef

14.

Schultz W (1998) Predictive reward signal of dopamine neurons. J Neurophysiol 80:1–27PubMed

15.

Abercrombie ED, Bonatz AE, Zigmond MJ (1990) Effects of l-DOPA on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats. Brain Res 525:36–44PubMedCrossRef

16.

Venton BJ, Zhang H, Garris PA, Phillips PE, Sulzer D, Wightman RM (2004) Real-time decoding of dopamine concentrating changes in the caudate-putamen during tonic and phasic firing. J Neurochem 89:1284–1295CrossRef

17.

Calabresi P (1993) Electrophysiology of dopamine–denervated striatal neurons; implications for Parkinson’s disease. Brain 116:433–452PubMedCrossRef

18.

Centonze D, Gubellini P, Picconi B, Calabresi P, Giacomini P, Bernardi G (1999) Unilateral dopamine denervation blocks corticostriatal LTP. J Neurophysiol 82:3575–3579PubMed

19.

Picconi B, Centonze D, Hakansson K, Bernardi G, Greengard P, Fisone G et al (2003) Loss of bidirectional striatal synaptic plasticity in l-DOPA-induced dyskinesia. Nat Neurosci 6:501–506PubMed

20.

Rodriguez M, Gonzalez J, Sabate M, Obeso J, Pereda E (2003) Firing regulation in dopaminergic cells: effect of the partial degeneration of nigrostriatal system in surviving neurons. Eur J Neurosci 18:53–60PubMedCrossRef

21.

Stephens B, Mueller AJ, Shering AF, Hood SH, Taggart P, Arbuthnott GW et al (2005) Evidence of a breakdown of corticostriatal connections in Parkinson’s disease. Neuroscience 132:741–754PubMedCrossRef

22.

Zaja-Milatovic S, Milatovic D, Schantz AM, Zhang J, Montine KS, Samii A et al (2005) Dendritic degeneration in neostriatal medium spiny neurons in Parkinson disease. Neurology 64:545–547PubMed

23.

Tremblay L, Filion M, Bedard PJ (1989) Responses of pallidal neurons to striatal stimulation in monkeys with MPTP-induced Parkinsonism. Brain Res 498:17–33PubMedCrossRef

24.

Filion M, Tremblay L, Bedard PJ (1988) Abnormal influences of passive limb movement on the activity of globus pallidus neurons in parkinsonian monkeys. Brain Res 444:165–176PubMedCrossRef

25.

De la Fuente-Fernandez R, Sossi V, Huang Z, Furtado S, Lu JQ, Calne DB et al (2004) Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson’s disease: implications for dyskinesias. Brain 127:2747–2754CrossRef

26.

Ballard PA, Tetrud JW, Langston JW (1985) Permanent human Parkinsonism due to 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP): seven cases. Neurology 35:949–956PubMed

27.

Bédard PJ, Di Paolo T, Falardeau P, Boucher R (1986) Chronic treatment with l-dopa, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [³H]spiperone binding. Brain Res 379:294–299PubMedCrossRef

28.

Pearce RK, Banerji T, Jenner P, Marsden CD (1998) De novo administration of ropinirole and bromocriptine induces less dyskinesia than l-dopa in the MPTP-treated marmoset. Mov Disord 13:234–241PubMedCrossRef

29.

Jenner P (2000) Factors influencing the onset and persistence of dyskinesia in MPTP-treated primates. Ann Neurol 47:S90–S99PubMed

30.

Blanchet PJ, Calon F, Martel JC, Bédard PJ, Di Paolo T, Walters RR et al (1995) Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys. J Pharmacol Exp Ther 272:854–859PubMed

31.

Bibbiani F, Costantini LC, Patel R, Chase TN (2005) Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates. Exp Neurol 192:73–78PubMedCrossRef

32.

Morissette M, Goulet M, Soghomonian JJ, Blanchet PJ, Calon F, Bédard PJ et al (1997) Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with l-DOPA therapy. Brain Res Mol Brain Res 49:55–62PubMedCrossRef

33.

Aubert I, Guigoni C, Hakansson K, Li Q, Dovero S, Barthe N et al (2005) Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann Neurol 57:17–26PubMedCrossRef

34.

Calon F, Grondin R, Morissette M, Goulet M, Blanchet PJ, Di Paolo T et al (2000) Molecular basis of levodopa-induced dyskinesias. Ann Neurol 47:70–78

35.

Cenci MA, Tranberg A, Andersson M, Hilbertson A (1999) Changes in the regional and compartmental distribution of FosB- and JunB-like immunoreactivity induced in the dopamine-denervated rat striatum by acute or chronic l-dopa treatment. Neuroscience 94:515–527PubMedCrossRef

36.

Calon F, Birdi S, Rajput AH, Hornykiewicz O, Bedard PJ, Di Paolo T (2002) Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias. J Neuropathol Exp Neurol 61:186–196PubMed

37.

Boraud T, Bezard E, Bioulac B, Gross CE (2001) Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP-treated monkey. Brain 124:546–557PubMedCrossRef

38.

Brown P, Oliviero A, Mazzone P, Insola A, Tonali P, Di Lazzaro V (2001) Dopamine dependency of oscillations between subthalamic nucleus and pallidum in Parkinson’s disease. J Neurosci 21:1033–1038PubMed

39.

Juncos JL, Engber TM, Raisman R, Susel Z, Thibaut F, Ploska A et al (1989) Continuous and intermittent levodopa differentially affect basal ganglia function. Ann Neurol 25:473–478PubMedCrossRef

40.

Engber TM, Susel Z, Juncos JL, Chase TN (1989) Continuous and intermittent levodopa differentially affect rotation induced by D-1 and D-2 dopamine agonists. Eur J Pharmacol 168:291–298PubMedCrossRef

41.

Engber TM, Susel Z, Kuo S, Gerfen CR, Chase TN (1991) Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats. Brain Res 552:113–118PubMedCrossRef

42.

Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE (2000) A 5 year study of the incidence of dyskinesia in patients with early parkinson’s disease who were treated with ropinirole or levodopa. N Engl J Med 342:1484–1491PubMedCrossRef

43.

Parkinson Study Group (2000) Pramipexole versus levodopa as initial treatment for Parkinson disease. JAMA 284:231–238CrossRef

44.

Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C et al (2003) Slower progression of Parkinson’s disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol 54:93–101PubMedCrossRef

45.

Parkinson Study Group (2002) Dopamine transporter brain imaging to assess the effects of pramipexole versus levodopa on Parkinson disease progression. JAMA 287:1653–1661CrossRef

46.

Nutt JG, Obeso JA, Stocchi F (2000) Continuous dopamine receptor stimulation in advanced Parkinson’s disease. Trends Neurosci 23:109–115CrossRef

47.

Stocchi F, Ruggieri S, Vacca L, Olanow CW (2002) Prospective randomized trial of lisuride infusion versus oral levodopa in PD patients. Brain 125:2058–2066PubMedCrossRef

48.

Olanow CW, Fahn S, Muenter M et al (1994) A multi-center, double-blind, placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson’s disease. Mov Disord 9:40–47PubMedCrossRef

49.

Lieberman A, Olanow CW, Sethi K et al (1998) A multi-center double blind placebo-controlled trial of ropinirole as an adjunct to l-dopa in the treatment of Parkinson’s disease patients with motor fluctuations. Neurology 51:1057–1062PubMed

50.

Pinter MM, Pogarell O, Oertel WH (1999) Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson’s disease: a double blind, placebo controlled, randomised, multicentre study. J Neurol Neurosurg Psychiatry 66:436–441PubMedCrossRef

51.

Clarke CE, Deane KH (2001) Cabergoline for levodopa-induced complications in Parkinson’s disease. Cochrane Database Syst Rev 1:CD001518PubMed

52.

Talati R, Baker WL, Patel AA, Reinhart K, Coleman CI (2009) Adding a dopamine agonist to preexisting levodopa therapy versus levodopa therapy alone in advanced Parkinson’s disease: a meta analysis. Int J Clin Pract 63:613–623PubMedCrossRef

53.

Stocchi F, Hersh BP, Scott BL, Nausieda PA, Giorgi L (2008) Ease-PD Monotherapy Study Investigators. Ropinirole 24-h prolonged release and ropinirole immediate release in early Parkinson’s disease: a randomized, double-blind, non-inferiority crossover study. Curr Med Res Opin 24:2883–2895PubMedCrossRef

54.

Rascol O, Barone P, Hauser RA et al (2010) Pramipexole Switch Study Group Efficacy, safety, and tolerability of overnight switching from immediate- to once daily extended-release pramipexole in early Parkinson’s disease. Mov Disord 25:2326–2332PubMedCrossRef

55.

Hauser RA, Schapira AH, Rascol O et al (2010) Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson’s disease. Mov Disord 25:2542–2549PubMedCrossRef

56.

Jankovic J, Watts RL, Martin W, Boroojerdi B (2007) Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. Arch Neurol 64:676–682PubMedCrossRef

57.

Giladi N, Boroojerdi B, Korczyn AD, Burn DJ, Clarke CE, Schapira AH, SP513 investigators (2007) Rotigotine transdermal patch in early Parkinson’s disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord 22:2398–2404PubMedCrossRef

58.

Watts RL, Lyons KE, Pahwa R et al (2010) Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson’s disease. Mov Disord 25:858–866PubMedCrossRef

59.

Pahwa R, Stacy MA, Factor SA et al (2007) EASE-PD. Ropinirole 24-h prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology 68:1108–1115PubMedCrossRef

60.

Stocchi F, Giorgi L, Hunter B, Schapira AH. PREPARED: comparison of prolonged and immediate release ropinirole in advanced Parkinson’s disease. Mov Disord (in press)

61.

LeWitt PA, Lyons KE, Pahwa R, SP 650 Study Group (2007) Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology 68:1262–1267PubMedCrossRef

62.

Poewe WH, Rascol O, Quinn N et al (2007) Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson’s disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 6:513–520PubMedCrossRef

63.

Trenkwalder C, Kies B, Rudzinska M et al (2011) Rotigotine effects on early morning motor function and sleep in Parkinson’s disease: A double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord 1:90–99CrossRef

64.

Stocchi F (2005) Pathological gambling in Parkinson’s disease. Lancet Neurol 4:590–592PubMedCrossRef

65.

Driver-Dunckley E, Samanta J, Stacy M (2003) Pathological gambling associated with dopamine agonist therapy in Parkinson’s disease. Neurology 61:422–423PubMed

66.

Nirenberg MJ, Waters C (2006) Compulsive eating and weight gain related to dopamine agonist use. Mov Disord 21:524–529PubMedCrossRef

67.

Brodsky MA, Godbold J, Roth T, Olanow CW (2003) Sleepiness in Parkinson’s disease: a controlled study. Mov Disord 18:668–672PubMedCrossRef

68.

Zanettini R, Antonini A, Gatto G et al (2007) Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N Engl J Med 35:639–646

Title: Continuous dopaminergic stimulation and novel formulations of dopamine agonists
Author: Fabrizio Stocchi
Publication date: 01-05-2011
Publisher: Springer-Verlag
Published in: Journal of Neurology / Issue Special Issue 2/2011
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-011-6024-y

2024 ASCO Annual Meeting

Springer Medicine

Continuous dopaminergic stimulation and novel formulations of dopamine agonists

Abstract

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Special Issue 2/2011

Drug-induced impulse control disorders in Parkinson’s disease

Parkinson’s disease risk score: moving to a premotor diagnosis

When Parkinson’s disease patients go to sleep: specific sleep disturbances related to Parkinson’s disease

Parkinson’s disease: a multi-faceted disease

Treatment of dysautonomia in extrapyramidal disorders

Depression in Parkinson’s disease